Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $100.00 price target on the stock.

Several other analysts have also recently issued reports on MNPR. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. BTIG Research reiterated a “buy” rating and issued a $104.00 target price on shares of Monopar Therapeutics in a report on Wednesday, January 14th. Finally, Oppenheimer set a $115.00 price target on shares of Monopar Therapeutics and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Monopar Therapeutics has an average rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Stock Down 0.1%

Shares of NASDAQ MNPR opened at $67.34 on Thursday. The firm has a 50-day simple moving average of $72.56 and a 200-day simple moving average of $65.32. The stock has a market capitalization of $449.83 million, a price-to-earnings ratio of -19.58 and a beta of 1.46. Monopar Therapeutics has a 52 week low of $26.06 and a 52 week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.02). As a group, equities research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Quan Anh Vu bought 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average cost of $69.95 per share, with a total value of $104,925.00. Following the purchase, the chief financial officer directly owned 1,500 shares in the company, valued at approximately $104,925. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at $673,000. Jane Street Group LLC acquired a new stake in Monopar Therapeutics in the 1st quarter valued at about $377,000. AlphaQuest LLC boosted its stake in shares of Monopar Therapeutics by 46.8% in the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after buying an additional 569 shares during the period. Geode Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after buying an additional 48,379 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Monopar Therapeutics during the second quarter worth about $34,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.